Published in final edited form as:

J Am Chem Soc. 2010 October 6; 132(39): 13642–13644. doi:10.1021/ja1057828.

Catalytic Enantioselective Alkylative Dearomatization-Annulation: Total Synthesis and Absolute Configuration Assignment of Hyperibone K

Ji Qi, Aaron B. Beeler, Qiang Zhang, and John A. Porco Jr.*

Department of Chemistry and Center for Chemical Methodology and Library Development (CMLD-BU), Boston University, Boston, Massachusetts 02215

Abstract

The asymmetric total synthesis of the polyprenylated acylphloroglucinol hyperibone K has been achieved using an enantioselective alkylative dearomatization-annulation process. NMR and computational studies were employed to probe the mode of action of a chiral phase-transfer (ion pair) catalyst.

The polyprenylated acylphloroglucinols (PPAP's) are a unique natural product class bearing the highly substituted and oxygenated bicyclo[3.3.1]nonane-1,3,5-trione framework (Figure 1). Clusianone (**1**) and its C7 epimer **2**, isolated from the floral resins of the *Clusia* species, have been shown to have cancer chemopreventive activity **1** as well as inhibit HIV infection. **2** Hyperibone K (**3**)³ and its structural isomer plukenetione A (**4**)⁴ (absolute stereochemistries unassigned) possess highly functionalized and unusual adamantane cores. In light of their challenging structures and promising biological activities, the PPAP family has garnered significant interest. Recently, asymmetric syntheses of (+)-clusianone (**1**)⁵ and (–)-hyperforin (**3**)⁶ were reported. In a previous study,⁷ we reported the synthesis of (±)-clusianone (**1**) employing a tandem alkylative dearomatization-annulation process. In this Communication, we report development of an enantioselective dearomatization-annulation protocol employing chiral phase-transfer (ion pair) catalysis and its application to the enantioselective synthesis of hyperibone K.

Our approach to hyperibone K (Figure 1, **3**) leverages a concise access to adamantane **5**⁷ (Scheme 1). We envisioned that **3** may be derived from allylic alcohol **6** by Lewis acid-promoted intramolecular cation cyclization.⁸ Allylic alcohol **6** may be derived from base-promoted retroaldol/vinyl metal addition⁹ of adamantane **5**, the latter which may be derived from alkylative dearomatization of clusiaphenone B (**7**).

Enantioselective approaches to clusianone, hyperibone K, and other PPAPs required development of an asymmetric alkylative dearomatization-alkylation process. A number of enantioselective dearomatization processes have been reported, chiefly involving oxidation

porco@bu.edu.

Supporting Information Available: Experimental procedures and characterization data for all new compounds. X-ray crystal structure coordinates and files in CIF format. This material is available free of charge via the Internet at <http://pubs.acs.org>.

chemistry, 10 with more limited studies reported involving alkylative dearomatization. 11 Our approach was inspired by a recent report from O'Donnell and coworkers 12 involving tandem conjugate addition-elimination using a chiral phase-transfer catalyst 13 derived from *Cinchona* alkaloids. We focused our initial studies on enantioselective dearomatization/alkylation of **7** with α -acetoxy enal **9**. 7 We first evaluated a number of chiral catalysts (**8a–g**; Figure 2) which were prepared from readily available *Cinchona* alkaloids. In initial experiments, we found that the desired dearomatization-annulation process using *O*-allyl-*N*-(9-anthracenylmethyl)cinchonidinium bromide (**8a**; 14 Figure 2) (CsOH·H₂O, 4 Å MS, CH₂Cl₂, –50 °C) proceeded smoothly to afford adamantane **5** in moderate yield (68%) and *ee* (75%) (Table 1, Entry 1). 15 However, a stoichiometric amount of catalyst **8a** was required to promote the reaction at –50 °C.

Recently, dimeric *Cinchona* alkaloid-derived phase-transfer catalysts have been reported, 16 which show very high reactivity and enantioselectivity in transformations including asymmetric alkylations 16a,d and nucleophilic epoxidation. 16c Accordingly, we first evaluated several reported dimeric catalysts (**8b–d**, Figure 2). Interestingly, we found that reactions catalyzed by the *meta*-substituted dimer **8b** (entry 2) afforded **5** in promising enantiomeric excess (68% *ee*) at a catalyst loading of 25 mol%. Catalysts with *ortho*- and *para*-substitution (**8c** and **8d**) showed poor enantioselectivity (11% *ee* and 20% *ee*). Through extensive structural modifications of the *meta*-dimeric catalyst, we identified the benzyl ether dimer **8e** which afforded **5** in moderate yield and good enantiomeric excess (48% yield, 84% *e.e.*).

We also evaluated heptanoate aldehyde **10** which displayed better reactivity having improved yields and shorter reaction times (Table 1, Entries 6–9). Further modification of catalyst **8e** by replacing the vinyl group with a 2-methylpropenyl moiety (catalyst **8f**, entry 8) led to improvement of enantioselectivity (90% *ee*). Use of (+)-cinchonine-derived catalyst **8g** afforded the opposite enantiomeric product (27*S*), albeit with lower enantioselectivity (–60% *ee*). We were able to unambiguously determine the absolute configuration of adamantane (–)-**5** by single crystal X-ray analysis after conversion to *p*-bromobenzoate ester **11** (Figure 3). 15, 17

Our synthetic approach to hyperibone K (**3**) features a retroaldol/addition process and is shown in Scheme 2. Dearomatization-annulation of **7** and aldehyde **10** proceeded smoothly to produce (–)-**5** (71%, 90% *ee*). Treatment of **5** with LDA, followed by addition of 2-methyl-1-propenyl magnesium bromide, 18 afforded allylic alcohol **6** which was produced from the retroaldol intermediate **12** followed by addition of 2-methyl-propenyl magnesium bromide. Intramolecular cation cyclization of **6** catalyzed by Sc(OTf)₃ successfully afforded (–)-**3** in moderate yield (50% yield, two steps), 8 thus establishing the absolute configuration of natural (+)-**3**. The high (>20:1) diastereoselectivity observed in the cyclization may be explained by analysis of cationic intermediate **13** which indicates a likely preference for conformation **13a** wherein the allylic cation is situated away from the *gem*-dimethyl moiety (Figure 4).

Although we developed an efficient catalyst system for enantioselective dearomatization-annulation, the mechanism and mode of action for the phase-transfer (ion pair) catalyst remained unsolved. To further understand catalyst mode of action, we considered a two-stage approach which would utilize both experimental and computational information. Stage 1 involved understanding the identity of the reactive substrate and relevant conformation(s) for the catalyst. Stage 2 involved elucidation of the substrate and catalyst complex leading to the observed enantiomer (–)-**5**.

Accordingly, initial ^1H NMR studies were conducted which indicated that, under standard reaction conditions (both achiral and chiral phase transfer catalysts), 80–90 % of clusiaphenone **7** exists in a dearomatized enolate form (*cf.* **14–17**, Figure 5).¹⁵ Accordingly, we propose that an enolate is likely the reactive species interacting with the catalyst.

We next turned our attention to elucidating the catalyst conformation. ^1H and ^{13}C NMR analysis of dimeric catalyst **8e** indicated that the catalyst adopts a C2 symmetrical conformation which is in agreement with a previously reported crystal structure of a related dimeric *Cinchona* alkaloid-derived catalyst.^{16c} We utilized NOESY experiments in conjunction with conformational analysis (mixed Monte Carlo Multiple Minimum (MCM)/Low-Mode Conformational Search (LMCS)) to determine likely conformations of catalyst **8e** in solution. By surveying the generated low energy conformations corresponding to key NOE interactions, we identified a single conformation (Figure 6) which was further optimized using DFT (B3LYP-63-1g). We also compared NOESY data of **8e** both alone and with substrate **7** allowing us to ascertain that the catalyst conformation did not shift significantly upon substrate complexation.¹⁵

Stage 2 relied on use of computational molecular docking to generate binding poses of the catalyst substrate complex. Literature reports have indicated the possibility of this approach highlighted by an example from Deslongchamps and coworkers who have utilized reverse docking to explore the configurational space of a flexible organocatalyst around a rigid catalyst-free transition state.²⁰ We utilized CDOCKER (a CHARMM-based docking program) to systematically pose the flexible substrate (acylphloroglucinol) within a static catalytic site and conduct low-level energy calculations for each pose. We also combined these studies with ROESY data of the substrate catalyst complex which illuminated key intermolecular interactions.¹⁵

As there are several possible enolates which may be operative (*cf.* Figure 5), we conducted docking studies on each. Docking experiments provided over 100 poses for enolates **14 – 17** bound to **8e** which were quickly reduced to a single pose for each enolate through a series of criteria: 1) correlation with ROESY data; 2) potential for ion-pair interactions (2 – 4 Å); and 3) substrate availability for Michael addition. The selected pose for each enolate was further optimized by DFT (B3LYP-63-1g).¹⁵ Poses meeting most of these criteria for each substrate were very similar regarding placement of the dearomatized enolate in the catalyst cavity.

Utilizing a pose which meets all of the criteria above, we developed a working model for the phase-transfer (ion pair) catalyst-mediated dearomatization-annulation with **8e** and enolate **15** (Figure 7). The preferred binding mode appears to be one in which the *para*-enolate oxygen is placed near a quaternary nitrogen center to form a tight ion pair and the dearomatized cyclohexadienone is aligned near the top of the aromatic linker. The lower energy poses situate the substrate such that the pseudo-axial proton derived from dearomatization is oriented away from the catalyst (Figure 7, a).¹⁵ In this orientation, substrates **15** and **17** appear to have more optimal ion pairing (Figure 7, a) with the more accessible ammonium center while substrates **14** and **16** are situated such that the charge bearing oxygen is paired with the less accessible ammonium center.¹⁵ The pose illustrated in Figure 7 also satisfies the major intermolecular interactions identified by ROESY experiments (Figure 7, a).¹⁵ Furthermore, poses utilizing substrates **15** and **17** may lead to the correct stereochemical outcome ((-)-**5**) while poses with **14** and **16** would afford the opposite configuration.¹⁵ Based on the model of catalyst **8e** and substrate **15**, it is apparent that a key binding element involves hydrophobic interaction of a substrate prenyl group in a

hydrophobic cleft of the catalyst formed by the vinyl and *O*-benzyl groups (Figure 7, b), both of which were shown to be critical for enantioselectivity (*cf.* Table 1). 17

In summary, we have developed an enantioselective alkylative dearomatization annulation process using dimeric chiral phase-transfer (ion pair) catalysts. The total synthesis and absolute configuration assignment of hyperibone K have been achieved by application of the asymmetric dearomatization process. NMR and computational studies were employed to illuminate the mode of action for the phase-transfer (ion pair) catalyst. Further studies utilizing molecular docking for mechanistic understanding of phase-transfer catalysis are ongoing and will be reported in due course.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the National Institutes of Health (GM-073855), the National Science Foundation (0848082), Merck Research Laboratories, and Wyeth for research support and Dr. Sujata Bardhan (Boston University) for providing catalysts and helpful discussions, and Dr. Paul Ralifo (Boston University) for assistance with NMR experiments. We thank the NSF for the high resolution mass spectrometer (CHE-0443618) used in this work.

References

1. Ito C, Itoigawa M, Miyamoto Y, Onoda S, Rao KS, Mukainaka T, Tokuda H, Nishino H, Furukawa H. *J Nat Prod.* 2003; 66:206–209. [PubMed: 12608850]
2. Piccinelli AL, Cuesta-Rubio O, Chica MB, Mahmood N, Pagano B, Pavone M, Barone V, Rastrelli L. *Tetrahedron.* 2005; 61:8206–8211.
3. Tanaka N, Takaishi Y, Shikishima Y, Nakanishi Y, Bastow K, Lee KH, Honda G, Ito M, Takeda Y, Kodzhimatov OK, Ashurmetov O. *J Nat Prod.* 2004; 67:1870–1875. [PubMed: 15568778]
4. Henry GE, Jacobs H, Sean Carrington CM, McLean S, Reynolds WF. *Tetrahedron Lett.* 1996; 37:8663–8666.
5. Rodeschini V, Simpkins NS, Wilson C. *J Org Chem.* 2007; 72:4265–4267. [PubMed: 17465570]
6. Shimizu Y, Shi SL, Usuda H, Kanai M, Shibasaki M. *Angew Chem, Int Ed.* 2010; 49:1103–1106.
7. Qi J, Porco JA Jr. *J Am Chem Soc.* 2007; 129:12682–12683. [PubMed: 17902679]
8. Noji M, Konno Y, Ishii K. *J Org Chem.* 2007; 72:5161–5167. [PubMed: 17553555]
9. (a) Quesnel Y, Toupet L, Duhamel L, Duhamel P, Poirier JM. *Tetrahedron: Asymm.* 1999; 10:1015–1018. (b) Carlier PR, Lo CWS, Lo MMC, Wan NC, Williams ID. *Org Lett.* 2000; 2:2443–2445. [PubMed: 10956517]
10. (a) Ding F, Valahovic MT, Keane JM, Anstey MR, Sabat MI, Trindle CO, Harman WD. *J Org Chem.* 2004; 69:2257–2267. [PubMed: 15049617] (b) Zhu J, Grigoriadis NP, Lee JP, Porco JA Jr. *J Am Chem Soc.* 2005; 127:9342–9343. [PubMed: 15984841] (c) Dong S, Zhu J, Porco JA Jr. *J Am Chem Soc.* 2008; 130:2738–2739. [PubMed: 18266375] (d) Mejorado LH, Pettus TRR. *J Am Chem Soc.* 2006; 128:15625–15631. [PubMed: 17147370] (e) Vo NT, Pace RDM, O'Hara F, Gaunt MJ. *J Am Chem Soc.* 2008; 130:404–405. [PubMed: 18081291] (f) Dohi T, Maruyama A, Takenage N, Senami K, Minamitsuji Y, Fujioka H, Caemmerer S, Kita Y. *Angew Chem, Int Ed.* 2008; 47:3787–3790.
11. (a) Lovchik MA, Goekeb A, Fráter G. *Tetrahedron: Asymm.* 2006; 17:1693–1699. (b) Garcia-Fortanet J, Kessler F, Buchwald SL. *J Am Chem Soc.* 2009; 131:6676–6677. [PubMed: 19388652]
12. Ramachandran PV, Madhi S, Bland-Berry L, Reddy MVR, O'Donnell MJ. *J Am Chem Soc.* 2005; 127:13450–13451. [PubMed: 16190680]
13. (a) O'Donnell MJ. *Acc Chem Res.* 2004; 37:506–517. [PubMed: 15311949] (b) Lygo B, Andrews BI. *Acc Chem Res.* 2004; 37:518–525. [PubMed: 15311950]
14. Corey EJ, Xu F, Noe MC. *J Am Chem Soc.* 1997; 119:12414–12415.

15. See Supporting Information for complete experimental details.
16. For select examples, see: (a) Jew S, Jeong BS, Yoo MS, Huh H, Park H. Chem Comm. 2001:1244–1245. (b) Andrus MB, Christiansen MA, Hicken EJ, Gainer MJ, Bedke KD, Harper KC, Mikkelsen SR, Dodson DS, Harris DT. Org Lett. 2007; 9:4865–4868. [PubMed: 17944480] (c) Jew S, Lee JH, Jeong BS, Yoo MS, Kim MJ, Lee YJ, Lee J, Choi S, Lee K, Lah MS, Park H. Angew Chem Int Ed. 2005; 44:1383–1385. (d) Lee JH, Yoo MS, Jung JH, Jew SS, Park H, Jeong BS. Tetrahedron. 2007; 63:7906–7915.
17. Interestingly, reaction of the *bis*-allyl variant of clusiaphenone B with **9** and catalyst **8e** (25 mol%) (–35°C, 42 h) afforded the corresponding adamantane alcohol in 11% yield. Olefin cross-metathesis afforded (–)-**5** in 39% *ee* which underscores the importance of the prenyl groups in substrate **7** for enantioselectivity.
18. Use of 2 equiv of 2-methyl-propenyl lithium also promoted retro-aldol/addition in comparable yield.
19. For dearomatization of phloroglucinols under basic conditions, see: Wang D, Hildenbrand K, Leitich J, Schuchmann HP, von Sonntag C. Z Naturforsch, B: Chem Sci. 1993; 48:478–482.
20. (a) Harriman DJ, Deslongchamps G. J Comput Aided Mol Des. 2004; 18:303–308. [PubMed: 15595458] (b) Harriman DJ, Deslongchamps G. J Mol Model. 2006; 12:793–797. [PubMed: 16496192]

Figure 1.
Polyisoprenylated Acylphloroglucinol Natural Products

Figure 2.
Dearomatization/Alkylation Using *Cinchona* Alkaloid-Derived Catalysts Using Various
Phase Transfer Catalysts

Figure 3.
Determination of the Absolute Configuration of **5**

Figure 4.
Allylic Cation Intermediate **13**

Figure 5.
Dearomatized Acyl Phloroglucinols **14–17**

Figure 6.
Optimized Conformation of Catalyst **8e** with Key nOe's

Figure 7.
Proposed Binding Model of Catalyst **8e** and **15**.
a) Key interactions of **8e** and **15**. b) 1.4 Å Connolly surface.

Scheme 1.
Retrosynthetic Analysis for Hyperibone K

Scheme 2.
Total Synthesis of (-)-Hyperibone K

Table 1
Enantioselective Dearomatization of Clusiaphenone B Using Various Phase Transfer Catalysts

entry	aldehyde (1.05 equiv.)	catalyst (25 mol%)	time (h)	yield (%)	ee (%)
1	9	8a (1 equiv.)	15	68	75 (27R)
2	9	8b	22	41	68 (27R)
3	9	8c	22	22	11 (27R)
4	9	8d	22	~10	20 (27R)
5	9	8e	22	48	84 (27R)
6	10	8b	10	65	76 (27R)
7	10	8e	10	61	86 (27R)
8	10	8f	10	71	90 (27R)
9	10	8g	10	53	-60 (27S)